The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...